AURKA and cancer: Notably, a number of pathways related to immune responses were also identified, including enrichment for Interleukin‐4 and Interleukin‐13 signalling (1 μM GZD824 in ARK1 and both doses in Ishikawa), PD‐1, PD‐L1 cancer immunotherapy pathway, IL‐6 and IL‐8 signalling (1 μM GZD824 in ARK1) and Immunogenic Cell Death Signalling Pathway (0.1 μM GZD824 in Ishikawa).